Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy-Reference-Cited by-同舟云学术

Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy

Published:2021-11-11 Issue:2 Volume:82 Page:245-253
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Tryggestad Anne M. A.¹^ORCID,Axcrona Karol²³^ORCID,Axcrona Ulrika⁴,Bigalke Iris¹⁵,Brennhovd Bjørn²,Inderberg Else M.¹^ORCID,Hønnåshagen Turid K.¹,Skoge Lisbeth J.¹,Solum Guri¹,Sæbøe‐Larssen Stein¹,Josefsen Dag¹,Olaussen Richard W.¹,Aamdal Steinar⁶^ORCID,Skotheim Rolf I.⁷^ORCID,Myklebust Tor Å.⁸⁹^ORCID,Schendel Dolores J.¹⁰^ORCID,Lilleby Wolfgang¹^ORCID,Dueland Svein⁶^ORCID,Kvalheim Gunnar¹^ORCID

Affiliation:

1. Department of Oncology Oslo University Hospital HF Oslo Norway

2. Department of Urology Oslo University Hospital HF Oslo Norway

3. Department of Urology Akershus University Hospital HF Oslo Norway

4. Department of Pathology Oslo University Hospital HF Oslo Norway

5. BioNTech IMFS GmbH Idar‐Oberstein Germany

6. Department for Clinical Research Oslo University Hospital HF Oslo Norway

7. Department of Molecular Oncology Oslo University Hospital HF Oslo Norway

8. Department of Registration Cancer Registry Norway Oslo Norway

9. Department of Research and Innovation Møre and Romsdal Hospital Trust Ålesund Norway

10. Medigene Immunotherapies GmbH Munich Germany

Funder